Aug 19, 2021
NCT05014646: Phase 2: Leflunomide for High-Risk Smoldering MM in African-Am. & European-Am. Patients
NCT05014646: Phase 2: Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American...
178
Aug 19, 2021
NCT05014412: Phase 1/2: Elranatamab in MM That Has Come Back or Has not responded - MagnetisMM-9
MagnetisMM-9 NCT05014412: Phase 1/2: A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That...
366
Aug 11, 2021
NCT04764942: Phase 1/2: Selinexor, Pom, Dex +/- Carfilzomib RRMM Multiple Myeloma, The SCOPE Trial
NCT04764942: Phase 1/2: Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With...
149
Aug 9, 2021
NCT04998747: Phase 1: A Study of Subcutaneous (SC) AMG 701 in RRMM Myeloma - (ProxiMMity-1)
Pavurutamab NCT04998747: Phase 1: A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma...
150
Aug 6, 2021
NCT04816526: Phase 2 - Descartes-08 anti-BCMA-CAR-mRNA-transf. auto CD8+ T cells Consolidation MRD+
NCT04816526: Phase 2 - Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After...
227
Aug 6, 2021
NCT04910568: Phase 1b - Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma...
855
Aug 6, 2021
NCT04973605: Phase 1/2: BGB-11417 in Monotherapy and With Carfilzomib-dex in RRMM and t(11;14)
NCT04973605: Phase 1/2: A Phase 1b/2 Study of BGB-11417 in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in...
59
Aug 5, 2021
NCT04975997: Phase 3: IberDd Versus DVd in Participants With Relapsed Refractory Myeloma - EXCALIBER
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in...
235
Aug 5, 2021
NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants RRMM
NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple...
760
Aug 4, 2021
NCT04960579: Phase 1: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Multiple Myeloma
NCT04960579: Phase 1: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM) NCT04960579: Phase 1:...
128
Jul 31, 2021
18th International Myeloma Workshop : September 8 - 11, 2021 - Vienna, Austria
18th International Myeloma Workshop September 8 - 11, 2021 - Vienna, Austria The International Myeloma Workshop is the defining meeting...
355
Jul 31, 2021
2021 SOHO Annual meeting : Ninth annual meeting Society of Hematologic Oncology Sep. 8-11, 2021.
The Society of Hematologic Oncology's Ninth Annual Meeting is scheduled as a virtual event on September 8-11, 2021. The focus of the...
184